Allogeneic hematopoietic cell transplantation for acute myeloid leukemia during first complete remission: a clinical perspective
M Yanada - International journal of hematology, 2015 - Springer
Allogeneic hematopoietic cell transplantation (HCT) is the most potent therapy for preventing
relapse of acute myeloid leukemia (AML). Although its efficacy is compromised by a high risk …
relapse of acute myeloid leukemia (AML). Although its efficacy is compromised by a high risk …
The evolving concept of indications for allogeneic hematopoietic cell transplantation during first complete remission of acute myeloid leukemia
M Yanada - Bone Marrow Transplantation, 2021 - nature.com
The long-standing debate of whether patients with acute myeloid leukemia (AML) should
proceed to allogeneic hematopoietic cell transplantation (HCT) during first complete …
proceed to allogeneic hematopoietic cell transplantation (HCT) during first complete …
Role of alternative donor allogeneic hematopoietic stem cell transplantation in patients with intermediate-or poor-risk acute myeloid leukemia in first complete …
S Yano, H Yokoyama, M Yanada, J Mori… - Bone marrow …, 2019 - nature.com
Allogeneic hematopoietic stem cell transplantation (HCT) offers the most effective prevention
of relapse and has significant overall survival (OS) benefits for patients with acute myeloid …
of relapse and has significant overall survival (OS) benefits for patients with acute myeloid …
Allogeneic haemopoietic transplantation for acute myeloid leukaemia in second complete remission: a registry report by the Acute Leukaemia Working Party of the …
MH Gilleece, M Labopin, BN Savani, I Yakoub-Agha… - Leukemia, 2020 - nature.com
Allogeneic haemopoietic cell transplant (allo-HCT) may be curative in acute myeloid
leukaemia (AML) in second complete remission (CR2) but the impact of reduced intensity …
leukaemia (AML) in second complete remission (CR2) but the impact of reduced intensity …
Efficacy of allogeneic hematopoietic stem cell transplantation depends on cytogenetic risk for acute myeloid leukemia in first disease remission: a metaanalysis
BACKGROUND The efficacy of allogeneic hematopoietic stem cell transplantation (allo‐
HSCT) from a human leukocyte antigen‐identical sibling donor remains controversial for …
HSCT) from a human leukocyte antigen‐identical sibling donor remains controversial for …
Early related or unrelated haematopoietic cell transplantation results in higher overall survival and leukaemia-free survival compared with conventional chemotherapy …
N Basara, A Schulze, U Wedding, M Mohren… - Leukemia, 2009 - nature.com
Between 1996 and 2004, a total of 708 patients were enrolled in the acute myeloid
leukaemia (AML)'96 and '02 studies of the East German Study Group (OSHO). Of these, 138 …
leukaemia (AML)'96 and '02 studies of the East German Study Group (OSHO). Of these, 138 …
Allogeneic hematopoietic stem-cell transplantation in patients with acute myeloid leukemia in first complete remission: new answers for an old question
A Shimoni, A Nagler - Leukemia, 2005 - nature.com
Allogeneic hematopoietic stem-cell transplantation (allo-SCT) has an established role in the
treatment of patients with acute myeloid leukemia (AML). Although the majority of adult …
treatment of patients with acute myeloid leukemia (AML). Although the majority of adult …
Acute myeloid leukemia: when to transplant in first complete remission
BT Hill, EA Copelan - Current hematologic malignancy reports, 2010 - Springer
Allogeneic hematopoietic stem cell transplantation (HSCT) is commonly used to treat acute
myeloid leukemia (AML) because it is potentially curative when other therapies have a low …
myeloid leukemia (AML) because it is potentially curative when other therapies have a low …
[HTML][HTML] Outcome of patients with acute myeloid leukemia (AML) undergoing allogeneic hematopoietic stem cell transplantation (HSCT) beyond first complete …
G Evers, DW Beelen, J Braess, C Sauerland, HJ Kolb… - Blood, 2018 - Elsevier
Introduction Despite substantial progress in the treatment of newly diagnosed AML, 20% to
40% of patients do not achieve remission with conventional induction chemotherapy. In …
40% of patients do not achieve remission with conventional induction chemotherapy. In …
Recent advances in allogeneic hematopoietic cell transplantation for acute myeloid leukemia
A Gomez-Arteaga, B Gyurkocza - Current Opinion in Hematology, 2020 - journals.lww.com
Recent advances in allogeneic hematopoietic cell transplanta... : Current Opinion in
Hematology Recent advances in allogeneic hematopoietic cell transplantation for acute myeloid …
Hematology Recent advances in allogeneic hematopoietic cell transplantation for acute myeloid …